Marksans Pharma announced that its wholly owned UK subsidiary, Relonchem, has received marketing authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for mefenamic acid 250 mg and 500 mg film-coated tablets. The approval further expands Relonchem’s growing footprint in the UK generics market.

This is the latest in a series of MHRA approvals for the company. Earlier this month, Relonchem received marketing authorisation for Exemestane 25 mg film-coated tablets. In September, the company secured approval for moxonidine tablets in 200 mcg and 400 mcg strengths.

In August, Relonchem also obtained MHRA clearance for multiple metformin products, including Metformin Hydrochloride Relonchem 500 mg, 750 mg and 1000 mg Prolonged Release Tablets.

With more than 400 product licences, Relonchem offers a diverse portfolio of own-label pharmaceutical products in the UK across key therapeutic areas such as diabetes, hypertension, depression, oncology, gastroenterology, virology, allergy management and pain relief.